Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
303.53
-4.29 (-1.39%)
At close: Oct 23, 2026, 4:00 PM EDT
303.53
0.00 (0.00%)
After-hours: Oct 23, 2026, 4:10 PM EDT
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Ligand Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $344.25. The average 1-year stock price forecast is 13.42% higher than the current stock price, while the lowest is $247 (-18.62%) and the highest is $397 (+30.79%).
Price Target: $344.25 (+13.42%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 8 | 8 |
| Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 10 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Reiterates $388 → $406 | Buy | Reiterates | $388 → $406 | +33.76% | Oct 19, 2026 |
| Barclays | Barclays | Buy Initiates $345 | Buy | Initiates | $345 | +13.66% | Sep 25, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $358 | Buy | Maintains | $358 | +17.95% | Sep 24, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 23, 2026 |
| Citi | Citi | Buy Maintains $390 → $397 | Buy | Maintains | $390 → $397 | +30.79% | Sep 23, 2026 |
Financial Forecast
Revenue This Year
289.64M
from 268.09M
Increased by 8.04%
Revenue Next Year
381.49M
from 289.64M
Increased by 31.71%
EPS This Year
9.31
from 8.13
Increased by 14.46%
EPS Next Year
11.95
from 9.31
Increased by 28.42%
EPS and Forward PE are based on non-GAAP adjusted numbers.